Polymer Free Everolimus
Eluting Coronary Stent System
World's Longest Studied
Drug Eluting Stent
New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance.
Probucol - For Optimal Drug Release
Less Polymeric Load Compared to Other DES
- One million pores per cm2 with average depth of 2 µm ensures optimum drug release with minimal use of polymer
- Shellac Resin ensures better drug-polymer binding with negligible polymer flaking during stent expansion
- Drug and Polymer are co-released in 6-9 months leaving behind bare metal stent surface
Abluminal Coating and Better Endothelialisation
- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis
Technical Specification
Ordering Information
Compliance Chart
Technical Data
Clinical Studies
Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.
*As per Clinical data with SS stent using similar microporous surface and drug coating technology
